Similarly, of the 913 patients who underwent GT in Post, 623 breast cancer patients were included, excluding ovarian cancer patients and those who underwent RRSO at or below the recommended age (35 years for BRCA1 and 40 years for BRCA2). The gene discussed is BRCA2; the disease is ovarian carcinoma.